Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes
CK Cho, P Kang, CG Jang, SY Lee, YJ Lee… - Archives of Pharmacal …, 2023 - Springer
Irbesartan, a potent and selective angiotensin II type-1 (AT1) receptor blocker (ARB), is one
of the representative medications for the treatment of hypertension. Cytochrome P450 (CYP) …
of the representative medications for the treatment of hypertension. Cytochrome P450 (CYP) …
CYP2C19 genotype and sodium channel blockers in lacosamide-treated children with epilepsy: two major determinants of trough lacosamide concentration or clinical …
Y Li, HL Guo, J Wang, YY Zhang… - Therapeutic …, 2024 - journals.sagepub.com
Background: The widespread clinical use of lacosamide (LCM) has revealed significant
individual differences in clinical response, with various reported influencing factors …
individual differences in clinical response, with various reported influencing factors …
The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsy
Background Epilepsy is a common neurological disease but around 30% of patients fail to
respond to antiepileptic drug (AED) treatment. Genetic variation of the ATP-binding cassette …
respond to antiepileptic drug (AED) treatment. Genetic variation of the ATP-binding cassette …